KR20180096633A - Il23-길항제에 대한 임상적 반응의 예측인자로서의 ccl20 - Google Patents

Il23-길항제에 대한 임상적 반응의 예측인자로서의 ccl20 Download PDF

Info

Publication number
KR20180096633A
KR20180096633A KR1020187017346A KR20187017346A KR20180096633A KR 20180096633 A KR20180096633 A KR 20180096633A KR 1020187017346 A KR1020187017346 A KR 1020187017346A KR 20187017346 A KR20187017346 A KR 20187017346A KR 20180096633 A KR20180096633 A KR 20180096633A
Authority
KR
South Korea
Prior art keywords
ccl20
level
patient
antibody
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187017346A
Other languages
English (en)
Korean (ko)
Inventor
로버트 더블유. 3세 조간타스
크리스 모어하우스
브랜든 힉스
코우츠브 라네이드
케이티 슈트라이허
윌리엄 리스
메이나 리앙
라파옐라 파기오니
징 리
인나 베인슈타인
옌-와 리
징징 첸
로버트 에이. 주니어 가세르
Original Assignee
암젠 인크
메디뮨 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 암젠 인크, 메디뮨 엘엘씨 filed Critical 암젠 인크
Publication of KR20180096633A publication Critical patent/KR20180096633A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020187017346A 2015-12-22 2016-12-16 Il23-길항제에 대한 임상적 반응의 예측인자로서의 ccl20 Withdrawn KR20180096633A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562271156P 2015-12-22 2015-12-22
US62/271,156 2015-12-22
PCT/US2016/067120 WO2017112536A1 (en) 2015-12-22 2016-12-16 Ccl20 as a predictor of clinical response to il23-antagonists

Publications (1)

Publication Number Publication Date
KR20180096633A true KR20180096633A (ko) 2018-08-29

Family

ID=59091179

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187017346A Withdrawn KR20180096633A (ko) 2015-12-22 2016-12-16 Il23-길항제에 대한 임상적 반응의 예측인자로서의 ccl20

Country Status (12)

Country Link
US (2) US11220541B2 (https=)
EP (1) EP3393515A4 (https=)
JP (2) JP2019508370A (https=)
KR (1) KR20180096633A (https=)
CN (1) CN108472367A (https=)
AU (1) AU2016379157A1 (https=)
BR (1) BR112018012626A2 (https=)
CA (1) CA3007098A1 (https=)
IL (1) IL259704A (https=)
MX (1) MX2018007589A (https=)
RU (1) RU2018124603A (https=)
WO (1) WO2017112536A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
CN108290058B (zh) 2015-09-17 2023-05-16 美国安进公司 使用il23途径生物标志物预测il23拮抗剂的临床应答
IL326284A (en) * 2018-09-24 2026-04-01 Janssen Biotech Inc A safe and effective method for treating ulcerative colitis with an anti-IL12/IL23 antibody
CN108957014A (zh) * 2018-09-27 2018-12-07 郑州大学第附属医院 结直肠癌血清标志物、表达评估方法、试剂盒及应用
EP3946592A4 (en) * 2019-03-26 2023-01-04 Astrazeneca Collaboration Ventures, LLC PATIENT POPULATIONS LIKELY TO BENEFIT FROM IL23 ANTAGONIST THERAPY
CN116782827A (zh) 2020-11-30 2023-09-19 明德拉公司 微针装置和方法以及皮肤病状测定
CN113092652B (zh) * 2021-03-19 2022-09-30 浙江工商大学 一种用于评估个体过敏程度的试剂盒
CN114113630B (zh) * 2021-11-24 2023-07-28 中南大学湘雅医院 Serpinb3/b4作为靶点在玫瑰痤疮等炎症性皮肤病治疗药物中的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8318754D0 (en) 1983-07-11 1983-08-10 Fagerhol M K F Human proteins anti-sera test kits
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5455160A (en) 1993-05-27 1995-10-03 Fagerhol; Magne K. Diagnostic test and kit for disease or disorders in the digestive system
AU4790597A (en) 1996-11-01 1998-05-29 Nycomed Pharma As Process for the extraction of proteins
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ZA986596B (en) 1997-07-25 1999-02-08 Schering Corp Mammalian cytokine related reagents
WO2005086835A2 (en) 2004-03-05 2005-09-22 Archemix Corp. Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics
CA2565701A1 (en) 2004-05-06 2005-11-17 Jonathan M. Barasch Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
KR100681763B1 (ko) 2005-02-28 2007-02-15 재단법인 목암생명공학연구소 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법
SI2452694T1 (sl) 2005-06-30 2019-05-31 Janssen Biotech, Inc. Protitelesa proti-IL-23, sestavki in postopki uporabe
DE602006015830D1 (de) 2005-08-25 2010-09-09 Lilly Co Eli Anti-il-23-antikörper
PT1931710T (pt) 2005-08-31 2017-03-28 Merck Sharp & Dohme Anticorpos anti-il-23 manipulados
BRPI0619118A2 (pt) 2005-12-02 2011-09-13 Genentech Inc composições e métodos para o tratamento de doenças e desordens associadas com a sinalização de citocina
HUE034269T2 (en) 2005-12-29 2018-02-28 Janssen Biotech Inc Human anti-IL-23 antibodies, preparations, methods and applications
WO2007098065A2 (en) 2006-02-17 2007-08-30 The United States Of America As Represented By The Department Of Veterans Affairs Human sodium channel isoforms
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
ES2708988T3 (es) 2007-02-23 2019-04-12 Merck Sharp & Dohme Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética
JP2010518858A (ja) 2007-02-23 2010-06-03 シェーリング コーポレイション 操作された抗−ｉｌ−２３ｐ１９抗体
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
US7833720B2 (en) 2008-03-14 2010-11-16 Exagen Diagnostics, Inc. Biomarkers for inflammatory bowel disease and irritable bowel syndrome
EP2331078B1 (en) 2008-08-27 2012-09-19 Merck Sharp & Dohme Corp. Lyophilized formulations of engineered anti-il-23p19 antibodies
US20100221752A2 (en) 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
US20100093552A1 (en) 2008-10-09 2010-04-15 Asit Panja Use and identification of biomarkers for gastrointestinal diseases
JP2012507723A (ja) * 2008-11-03 2012-03-29 シェーリング コーポレイション 炎症性腸疾患生物マーカーおよび関連治療方法
US20120128689A1 (en) 2009-04-01 2012-05-24 Glaxo Group Limited Anti-il-23 immunoglobulins
WO2010129964A1 (en) 2009-05-08 2010-11-11 The Board Of Trustees Of The University Of Illinois Drug targets for prevention of arrhythmia in heart disease
US20120264917A1 (en) 2009-05-27 2012-10-18 Ablynx N.V. Biparatopic protein constructs directed against il-23
EP3309556B1 (en) 2009-06-25 2020-04-08 Prometheus Biosciences, Inc. Methods for diagnosing irritable bowel syndrome
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
CA2781654A1 (en) 2009-11-25 2011-06-03 Hua Gong Novel genomic biomarkers for irritable bowel syndrome diagnosis
PH12012501364A1 (en) 2010-01-15 2012-10-22 Amgen K A Inc Antibody formulation and therapeutic regimens
WO2012009760A1 (en) 2010-07-20 2012-01-26 Cephalon Australia Pty Ltd Anti-il-23 heterodimer specific antibodies
US8541180B1 (en) 2010-10-11 2013-09-24 Genova Diagnostics, Inc. Compositions and methods for assessing gastrointestinal health
MX2019000046A (es) 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.
BR112013017445A2 (pt) 2011-01-06 2016-08-23 Univ Illinois métodos de determinar a necessidade de um indivíduo para um desfibrilador cardíaco implantado (icd) e para uma terrapia antiarrítmica, de determinar o risco de um indivíduo para uma morte cardiáca súbita, para arritmias e para insuficiência cardíaca, de reduzir risco de morte cardíaca súbita em um indivíduo, kit, sistema, meio de armazenamento legível por computador, e, método implementado por um processador em um computador
WO2012158831A1 (en) 2011-05-16 2012-11-22 Prometheus Laboratories Inc. Performance of a biomarker panel for irritable bowel syndrome
NO336551B1 (no) 2011-06-21 2015-09-28 Magne Fagerhol Forbedret ELISA for kalprotektin i fekalprøve eller gastrointestinaltraktsprøve
NO20110895A1 (no) 2011-06-21 2012-12-24 Magne Fagerhol Kompetitive S100A9 immunoanalyser
WO2013132338A2 (en) 2012-03-06 2013-09-12 Calpro As Competitive immunoassay for calprotectin
WO2013132347A2 (en) 2012-03-06 2013-09-12 Calpro As Improved elisa immunoassay for calprotectin
WO2013152114A1 (en) 2012-04-03 2013-10-10 The Regents Of The University Of Michigan Biomarker associated with irritable bowel syndrome and crohn's disease

Also Published As

Publication number Publication date
CA3007098A1 (en) 2017-06-29
BR112018012626A2 (pt) 2018-12-04
EP3393515A4 (en) 2019-08-14
MX2018007589A (es) 2018-11-09
JP2019508370A (ja) 2019-03-28
IL259704A (en) 2018-07-31
JP2022031643A (ja) 2022-02-22
RU2018124603A3 (https=) 2020-04-06
WO2017112536A1 (en) 2017-06-29
EP3393515A1 (en) 2018-10-31
RU2018124603A (ru) 2020-01-24
US20220144935A1 (en) 2022-05-12
CN108472367A (zh) 2018-08-31
AU2016379157A1 (en) 2018-06-21
US20200262907A1 (en) 2020-08-20
US11220541B2 (en) 2022-01-11

Similar Documents

Publication Publication Date Title
JP7153775B2 (ja) Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
US20220144935A1 (en) Ccl20 as a predictor of clinical response to il23-antagonists
CN107001455B (zh) 利用hnl的诊断方法
Koyama et al. Significance of IgG4-positive cells in severe eosinophilic chronic rhinosinusitis
JP2012507723A (ja) 炎症性腸疾患生物マーカーおよび関連治療方法
HK1247287A1 (zh) 检测和定量il-13的方法和在诊断和治疗th2相关疾病中的用途
AU2016349113A1 (en) Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases
JP2017507322A (ja) ヒトペリオスチンを検出する新規アッセイ
JP2023058524A (ja) 関節リウマチの治療のための臨床応答バイオマーカーとしての抗ｐａｄ４自己抗体
JP2015502917A (ja) Ｔｓｌｐ処置のバイオマーカーとしてのｉｌ−１９
EP3242686B1 (en) Assay to detect human dpp-4
US20220373539A1 (en) Prediction of clinical response to il23-antagonists using il23 pathway biomarkers
HK1242740B (zh) 预测、诊断和治疗特发性肺纤维化的方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180619

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid